Tokyo’s Daiichi Sankyo (TYO: 4568) has submitted a supplemental New Drug Application (sNDA) for trastuzumab deruxtecan in Japan.
The firm wants to market the antibody-drug conjugate (ADC), which has been granted Sakigake, or priority review status, for people with HER2 positive metastatic gastric cancer.
Under the expedited review timetable, a decision is expected within six months.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze